Recombinant Mouse Ccl19 protein

• Cat.No.: Ccl19-623M
• Product Overview: Recombinant Mouse Ccl19 protein was expressed in Escherichia coli.

Specification

• Description: CCL19, also known as EBI1 Ligands chemokine (ELC) and macrophage inflammatory protein-3-beta, is encoded by the CCL19 gene which is located on chromosome 4 in mouse. The protein is expressed at high levels in thymus and lymph nodes, with intermediate levels in trachea and colon and low levels in stomach, lung and some other organs. CCL19 is signal through CCR7 and chemotaxis of T and B lymphocytes and myeloid progenitor cells.
• Source: E.coli
• Species: Mouse
• Form: Lyophilized from a 0.2μm filtered concentrated solution in PBS, pH 7.4.
• Bio-activity: Fully biologically active when compared to standard. The biological activity determined by a chemotaxis bioassay using human mature dendritic cells is in a concentration range of 10-100 ng/ml.
• Molecular Mass: Approximately 9.2 kDa, a single non-glycosylated polypeptide chain containing 83 amino acids.
• Protein length: 83
• AA Sequence: GANDAEDCCLSVTQRPIPGNIVKAF RYLLNEDGCRVPAVVFTTLRGYQLC APPDQPWVDRIIRRLKKSSAKNKGN STRRSPVS
• Endotoxin: Less than 1 EU/μg of rMuMIP-3β/CCL19 as determined by LAL method.
• Purity: >97% by SDS-PAGE and HPLC analysis.
• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 centigrade as supplied. 1 month, 2 to 8 centigrade under sterile conditions after reconstitution. 3 months, -20 to -70 centigrade under sterile conditions after reconstitution.
• Reconstitution: We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤-20 centigrade. Further dilutions should be made in appropriate buffered solutions.

Gene Information

• Gene Name: Ccl19
• Official Symbol: Ccl19
• Synonyms: CCL19; chemokine (C-C motif) ligand 19; C-C motif chemokine 19; chemokine CCL19; EBI1 ligand chemokine; EBI1-ligand chemokine; EBI-1 ligand chemokine; small inducible cytokine A19; small-inducible cytokine A19; EBV-induced molecule 1 ligand chemokine; epstein-Barr virus-induced molecule 1 ligand chemokine; ELC; CKb11; MIP3B; Scya19; exodus-3
• Gene ID: 24047
• mRNA Refseq: NM_011888
• Protein Refseq: NP_036018
• UniProt ID: O70460

Reviews

03/29/2021

The quality of the production is stable, and the batch-to-batch and intra-batch repeatability is good.

11/10/2020

CCL19 has a complete range of specifications and is suitable for experiments of different scales.

03/09/2020

The preparation is simple and we can do it ourselves.

Q&As

What are the limitations of research on CCL19?

There are still some limitations in the current research on CCL19, such as the lack of in-depth research on its specific mechanism of action and function, and the incomplete understanding of its relationship with diseases. In addition, since CCL19 is a multifunctional protein, regulating it may also have some side effects.

Why is CCL19 related to other chemokines or proteins?

It has a complex relationship with other chemokines or proteins. For example, it binds to the CCR7 receptor, which directs the migration of immune cells. In addition, CCL19 interacts with other chemokines and cytokines to jointly regulate immune responses.

What are the treatment strategies for CCL19?

Therapeutic strategies for CCL19 include inhibition of its expression, modulation of its activity, or use of gene therapy. For example, some studies have shown that the use of small molecule inhibitors or antibodies against CCL19 can inhibit its activity and thus treat some CCL19-related diseases. In addition, related diseases can also be treated by regulating the expression level of CCL19.

How can we better understand the role of CCL19 in disease?

In order to better understand the role of CCL19 in disease, further in-depth study of its specific mechanism of action and function is needed. In addition, it is also necessary to study the changes in its expression level and activity in different diseases, as well as its relationship with the occurrence and development of diseases. At the same time, it is also necessary to explore the clinical application prospects and effects of the therapeutic strategies that regulate them. This will contribute to the development of more effective treatments to improve outcomes and quality of life for patients with CCL19-related diseases.

What is the role of CCL19 in the immune system?

CCL19 is mainly involved in the recruitment and activation of immune cells. It is able to exert immune defense by binding to receptors on the cell surface to direct immune cells to migrate to the site of inflammation or infection. In addition, CCL19 is also able to regulate the activation and differentiation of immune cells, affecting the type and intensity of immune responses.

Are there new mechanisms of action or functions in recent studies of CCL19?

Recent studies have found that CCL19 is also involved in the production and maintenance of lymphatic vessels. These processes have an important impact on the migration of immune cells and the regulation of immune responses, and also provide new ideas for the treatment of some diseases related to CCL19.